TL;DR
- •Xanax (alprazolam) is a short-acting benzodiazepine with a half-life of 6-12 hours — making it one of the harder benzodiazepines to taper because of inter-dose withdrawal effects and severe rebound between doses.
- •Benzodiazepine withdrawal can be DANGEROUS — abrupt discontinuation can produce seizures. Tapers require prescriber supervision and should not be attempted without medical guidance.
- •A common strategy: switch from Xanax to Valium (diazepam, half-life 20-100 hours) at an equivalent dose, then taper Valium slowly. Valium's long half-life smooths the taper dramatically.
- •Hyperbolic tapering — smaller and smaller proportional reductions over months — is increasingly the standard for long-term benzodiazepine users. The Ashton Manual (Heather Ashton, 1999) is the foundational reference document.
- •Withdrawal symptoms can include severe anxiety, panic attacks, insomnia, tremors, sweating, GI disturbance, perceptual changes, and in some cases seizures. The "rebound" effect can feel worse than the original anxiety.
- •For patients on Xanax for anxiety, ketamine's NMDA mechanism offers an entirely different approach — and the rapid anxiolytic effect of ketamine can support the difficult benzodiazepine taper.
Why people decide to taper
- •Tolerance — the same dose no longer works as well
- •Dependence — physical need for the medication to feel "normal"
- •Cognitive side effects (memory, concentration, processing speed)
- •Concerns about long-term cognitive effects
- •Fall risk (especially in older adults)
- •Original anxiety in remission or being managed by other means
- •Concerns about the rebound-anxiety cycle (taking Xanax for anxiety caused by Xanax wearing off)
What withdrawal looks like
Xanax withdrawal can be SEVERE and includes risk of seizures. Symptoms typically begin within 6-24 hours of the last dose because of the short half-life. Common symptoms: severe anxiety (often worse than the original anxiety the medication treated), panic attacks, insomnia, tremors, sweating, nausea, GI disturbance, perceptual disturbances (heightened sensitivity to light/sound, depersonalization), muscle tension. Severe cases can include hallucinations, delirium, seizures. The "kindling" phenomenon means repeated withdrawal episodes can become progressively worse — making any single attempted cold-turkey particularly dangerous.
Typical taper timeline
Xanax tapers should be slow and supervised. The Ashton Manual recommends benzodiazepine tapers taking months to years — the longer the patient has been on the medication, the longer the taper. Short-term users (a few months): typically 3-6 months. Long-term users (years): often 1-2 years for safe, comfortable hyperbolic taper. Trying to compress benzodiazepine tapers frequently fails and produces dangerous withdrawal.
Taper approaches
Options to bring to your prescriber. The dose-by-dose plan belongs to your prescriber, not this page.
Switch to Valium first (Ashton approach)
Convert Xanax to equivalent-dose Valium (diazepam) — 1mg Xanax ≈ 20mg Valium. Then taper Valium slowly over months. Valium's much longer half-life (20-100 hours vs 6-12 for Xanax) smooths the taper enormously. This is the foundational approach described in the Ashton Manual.
Hyperbolic taper
Reduce by smaller and smaller proportional amounts over months. The standard "reduce 0.25mg every 2 weeks" approach often fails with Xanax because of inter-dose withdrawal. Reducing by 5-10% of current dose every 2-4 weeks is more tolerable.
Slow micro-tapers
For sensitive patients, daily micro-reductions (reducing by 0.0125mg per day at the end of taper) using compounded liquid alprazolam can be much more tolerable than weekly steps. Requires compounding pharmacy and prescriber coordination.
Inpatient detox for severe cases
For long-term high-dose users or those with prior severe withdrawal, supervised inpatient detox is sometimes appropriate. Medical supervision allows symptom management and seizure protection during the most-difficult phase.
Address underlying anxiety with ketamine
For patients on Xanax for anxiety, ketamine's NMDA mechanism offers an entirely different anxiolytic pathway. Ketamine can be started while the Xanax taper is in progress (with screening for safety) — the rapid anxiolytic effect of ketamine supports the withdrawal anxiety that often derails benzo tapers.
What’s specific to Xanax (Alprazolam)
Xanax's short half-life (6-12 hours) and high potency make it particularly problematic for long-term use. Patients often take it multiple times per day, and the inter-dose withdrawal — when plasma levels drop between doses — produces "between-dose anxiety" that can feel worse than the original condition. This creates a cycle where patients take Xanax to manage Xanax-withdrawal-anxiety. Switching to Valium changes the picture significantly because the long half-life maintains steady plasma levels. Xanax is available as 0.25mg/0.5mg/1mg/2mg tablets plus an XR formulation; the XR doesn't change the fundamental dependence profile but does smooth daily kinetics.
Where ketamine fits
For patients on Xanax for anxiety (the most common indication), ketamine offers an entirely different anxiolytic pathway through NMDA receptor antagonism. While benzodiazepine withdrawal is happening, the breakthrough anxiety can be partially supported by ketamine's anxiolytic effect — making the taper more tolerable. Tovani screens carefully for benzodiazepine-dependence status during eligibility consultation and coordinates with the patient's prescribing physician on the taper schedule. The long-term goal: address the underlying anxiety through a non-dependence-producing mechanism, allowing the benzodiazepine to be discontinued safely.
Check eligibility for ketamine therapy5-minute screening · Reviewed by a board-certified physician · FL & NJ
Frequently asked
Is benzodiazepine withdrawal really dangerous?
Yes — meaningfully more dangerous than antidepressant withdrawal. Severe benzodiazepine withdrawal can include seizures, delirium, and (rarely) death. This is why benzodiazepine tapers require medical supervision and should never be attempted cold-turkey from significant doses. The risk is real and is the structural reason for slow, supervised tapers.
How long should a Xanax taper take?
Much longer than most patients expect. Short-term users (a few months on the medication): 3-6 months of taper. Long-term users (years): often 1-2 years for a safe hyperbolic taper. Trying to compress these timelines is the main reason benzodiazepine tapers fail.
Should I switch to Valium before tapering?
For most long-term Xanax users, yes — this is the foundational approach described in the Ashton Manual. Equivalent-dose Valium (1mg Xanax ≈ 20mg Valium) followed by slow Valium taper is much more tolerable than direct Xanax tapers because of the half-life difference. Discuss with your prescriber.
Can ketamine help with the anxiety during benzodiazepine taper?
For many patients, yes. Ketamine's anxiolytic effect through NMDA antagonism provides a different mechanism for managing the breakthrough anxiety that often derails benzodiazepine tapers. Requires careful clinical coordination — the combination should be supervised by a physician familiar with both medications. Tovani screens for benzodiazepine status during consultation.
I've been on Xanax for 10 years. Is it too late to come off?
No. Long-term Xanax users can taper successfully — it just takes longer and requires more careful planning. The Ashton Manual's slow-taper approach (often 12-24 months for long-term users) has helped many patients off years of benzodiazepine use. Find a prescriber familiar with the Ashton approach; not all are, and a clinician comfortable with the slow timeline is essential.
Never taper without prescriber coordination
Withdrawal symptoms can mimic depression or anxiety relapse, and untreated relapse can be more dangerous than withdrawal. Stopping benzodiazepines abruptly can produce seizures. Bring this page to your prescriber as a conversation starter — they translate options into your specific plan.
References
- Murrough JW et al. 2013, American Journal of Psychiatry. Ketamine RCT in treatment-resistant depression — anxiety symptoms tracked alongside core depression response showed improvement, relevant for benzodiazepine-treated patients seeking mechanism alternatives. PMID 23982301
- Sanacora G et al. 2017, JAMA Psychiatry. APA consensus on ketamine in mood and anxiety disorders — addresses use in patients with complex pharmacology including benzodiazepine maintenance. PMID 28249076